Stockholm, Sweden-based Elekta develops precision radiation therapy to treat cancer. The FDA cleared its latest offering, the Comprehensive Motion Management (CMM) with True Tracking and automatic gating, earlier this year.
Krishna Institute of Medical Sciences (KIMS) in Hyderabad, one of India’s largest corporate healthcare groups, made the order. Dr. Bhaskar Rao Bollineni, KIMS chair and managing director, called Elekta’s technologies “cutting edge.”
“These devices and software will enable us to provide more personalized and precise treatments for various types of cancers, while minimizing side effects and improving quality of life,” said Bollineni. “We are committed to offering the best possible care to our patients and investing in innovation that can make a difference.”
The combination of solutions includes Elekta’s Unity MR-Linacs and the Esprit Leksell gamma knife systems. It also features the Versa HD linear accelerators, Flexitron brachytherapy afterloaders and Elekta One oncology software solutions.
“We are proud to collaborate with KIMS Hyderabad, one of the leading healthcare providers in India, to deliver our state-of-the-art radiation therapy solutions,” Elekta CEO Gustaf Salford said. “We believe that these devices will enhance the clinical capabilities and outcomes of their hospitals and benefit thousands of cancer patients. I look forward to a long-term partnership with KIMS Hyderabad and supporting their vision of providing world-class cancer care.”
KIMS Hyderabad, based in Telangana, operates 12 hospitals across Andhra Pradesh, Telangana and Maharashtra. Elekta expects the deployment of its equipment to take place in a phased manner. It anticipates the first installations during the fourth quarter of fiscal 2023/24, followed by deployment over three years.
